Whole-genome characterization of chemoresistant ovarian cancer
- PMID: 26017449
- DOI: 10.1038/nature14410
Whole-genome characterization of chemoresistant ovarian cancer
Erratum in
-
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. Nature. 2015. PMID: 26503049 No abstract available.
Abstract
Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.
Similar articles
-
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28414925
-
Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.J Pathol Clin Res. 2020 Oct;6(4):252-262. doi: 10.1002/cjp2.168. Epub 2020 May 11. J Pathol Clin Res. 2020. PMID: 32391646 Free PMC article.
-
Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.Int J Cancer. 2024 Jul 1;155(1):104-116. doi: 10.1002/ijc.34908. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447012
-
Acquired chemotherapy resistance in ovarian cancer.Ann Oncol. 2017 Nov 1;28(suppl_8):viii13-viii15. doi: 10.1093/annonc/mdx446. Ann Oncol. 2017. PMID: 29232469 Review.
-
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31. Ann Oncol. 2016. PMID: 27037296 Review.
Cited by
-
CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.Mod Pathol. 2016 Oct;29(10):1254-61. doi: 10.1038/modpathol.2016.101. Epub 2016 Jul 22. Mod Pathol. 2016. PMID: 27443516 Free PMC article.
-
When Genome Maintenance Goes Badly Awry.Mol Cell. 2016 Jun 2;62(5):777-87. doi: 10.1016/j.molcel.2016.05.021. Mol Cell. 2016. PMID: 27259208 Free PMC article. Review.
-
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175. Oncotarget. 2016. PMID: 27659536 Free PMC article.
-
Prediction of the treatment response in ovarian cancer: a ctDNA approach.J Ovarian Res. 2020 Oct 19;13(1):124. doi: 10.1186/s13048-020-00729-1. J Ovarian Res. 2020. PMID: 33076944 Free PMC article. Review.
-
Sorcin in Cancer Development and Chemotherapeutic Drug Resistance.Cancers (Basel). 2024 Aug 9;16(16):2810. doi: 10.3390/cancers16162810. Cancers (Basel). 2024. PMID: 39199583 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous